Objective: To evaluate the clinical efficacy of Qianlie’an (QLA) suppository via anal route administration in treating chronic prostatitis syndrome.Methods: A randomized open-labelled prospective controlled trial was carried out. The total of 120 patients with chronic prostatitis syndrome were randomly divided into 2 groups: 60 patients in the treated group who were treated with QLA suppository combined with ofloxacin

and the other 60 patients in the control group who were given ofloxacin alone. The efficacy was evaluated by WBC count in the expressed prostatic secretion (EPS) and the Chronic Prostatitis Symptom Index (CPSI) made by the National Institute of Health (NIH). The clinical effects were also observed in a 4-week follow-up.Results: All but six cases completed the trial and the follow-up. It showed that in the treated group recovery rate was 17. 2%

markedly effective rate 34. 5%

effective rate 32. 8%

total markedly effective rate 51. 7%

and total effective rate 84. 5%

all of which were superior to those in the control group (total markedly effective rate 32.1% and total effective rate 66.1%

respectively)

P < 0.01.Conclusion: Administration of QLA suppository via anal route combined with oral antibiotics is an effective therapy for chronic prostatitis syndrome. It can relieve the symptoms of chronic prostatitis syndrome markedly and rapidly. It is a new choice for treatment of the disease.